Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMIRAY study of JNJ-90301900 with concurrent chemoradiation in locally advanced head and neck squamous cell carcinoma
jRCT2031250716Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
Open-label trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with adverse events by severity. Started Mar 2026; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031250716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250716.